US equities
|
MU
$989.04
▼-3.88%
META
$742.96
▲+3.38%
NVDA
$226.32
▼-1.29%
SNDK
$1,487.33
▼-5.97%
SPCX
$163.42
▲+0.52%
MSFT
$541.15
▲+1.14%
AMD
$594.24
▼-2.28%
AAPL
$340.97
▲+1.29%
MU
$989.04
▼-3.88%
META
$742.96
▲+3.38%
NVDA
$226.32
▼-1.29%
SNDK
$1,487.33
▼-5.97%
SPCX
$163.42
▲+0.52%
MSFT
$541.15
▲+1.14%
AMD
$594.24
▼-2.28%
AAPL
$340.97
▲+1.29%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Kiora Pharmaceuticals, Inc. - Common Stock
(NQ:
KPRX
)
2.560
+0.020 (+0.79%)
Delayed Quote
Updated: 3:59 PM EDT, Oct 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Kiora Pharmaceuticals, Inc. - Common Stock
Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium
July 02, 2026
Encinitas, California--(Newsfile Corp. - July 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that it will participate in...
Via
Newsfile
Topics
Regulatory Compliance
Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model
June 18, 2026
Encinitas, California--(Newsfile Corp. - June 18, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today announced preclinical data showing that KIO-300, part...
Via
Newsfile
ENDRA Life Sciences (NASDAQ: NDRA) Targets MASLD and GLP-1 Imaging Bottleneck With TAEUS® as Stocks Under $5 Gain Attention Inside
April 07, 2026
Via
AB Newswire
MAG 8 Momentum: NIVF, TRAW, KPRX, PNPN.V Lead $3 Undercard Surge – More Stocks Inside!
June 04, 2025
Via
AB Newswire
Shares of Kiora Pharmaceuticals Inc. (KPRX) Rise to a New 52-Week High
September 27, 2022
Via
Investor Brand Network
Lytham Partners Announces KOL Panels and Participating Companies for its Fall 2024 Investor Conference
September 30, 2024
Phoenix, Arizona and New York, New York--(Newsfile Corp. - September 30, 2024) - Lytham...
Via
Newsfile
Lytham Partners Spring 2024 Investor Conference Starts Tomorrow, May 30, 2024
May 29, 2024
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and...
Via
Newsfile
Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease
May 10, 2024
Phase 2 trial for KIO-301 for the treatment of retinitis pigmentosa, in partnership with Théa Open Innovation, expected to be...
Via
Newsfile
AAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa
November 04, 2023
Topline Phase I/II First-in-Human Results Presented at AAO 2023Significant improvement in visual field, in concordance with trended improvements in visual...
Via
Newsfile
Kiora Pharmaceuticals Taps B2i Digital to Deploy Data-Driven Investor Awareness Program
August 22, 2023
Encinitas, California--(Newsfile Corp. - August 22, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), a clinical-stage biotechnology company developing novel therapies...
Via
Newsfile
Life Science Investor Forum: Presentations Now Available for Online Viewing
June 23, 2023
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Life Science Investor Forum Agenda Announced for June 22nd
June 20, 2023
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Stonegate Healthcare Reviews Retinitis Pigmentosa
December 14, 2022
Dallas, Texas--(Newsfile Corp. - December 14, 2022) - Stonegate Healthcare has published a new...
Via
Newsfile
Battling Blindness: Virtual Investor Event on Treatments for Retinitis Pigmentosa to Be Held October 19; Panelists include Kiora Pharmaceuticals, Foundation Fighting Blindness, and Retinal Surgeon Christine Kay, M.D.
September 28, 2022
Dallas, Texas--(Newsfile Corp. - September 28, 2022) - Stonegate Capital Partners will host a...
Via
Newsfile
Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc. (NASDAQ:KPRX, Formerly NASDAQ:EYEG) Investor Notice: Investigation
↗
February 15, 2022
San Diego, CA -- (SBWIRE) -- 02/15/2022 -- An investigation was announced for investors of Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc. (NASDAQ:KPRX, formerly NASDAQ:EYEG) shares...
Via
SBWire
Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc. (NASDAQ:KPRX, Formerly NASDAQ:EYEG) Investor Notice: Investigation Announced
↗
December 15, 2021
San Diego, CA -- (SBWIRE) -- 12/15/2021 -- An investigation was announced for investors of Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc. (NASDAQ:KPRX, formerly NASDAQ:EYEG) shares...
Via
SBWire
NASDAQ:KPRX, Formerly NASDAQ:EYEG Investor Alert: Investigation over Potential Wrongdoing at Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc.
↗
December 01, 2021
San Diego, CA -- (SBWIRE) -- 12/01/2021 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Kiora Pharmaceuticals, Inc f.k.a. EyeGate...
Via
SBWire
